As of May 30, 2026, Vertex Pharmaceuticals's top three insider holders are Reshma Kewalramani (Ceo President, 98.28K shares), Stuart A Arbuckle (Evp, Coo, 63.37K shares), Amit Sachdev (Evp Chief Patient Ext Af Off, 55.57K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Bruce I Sachs | - | 45,000 | 0 | 07 Aug, 2025 |
| Lloyd Carney | - | 6,315 | 0 | 20 Nov, 2025 |
| Margaret G Mcglynn | - | 178 | 0 | 03 May, 2022 |
| Charles F Jr Wagner | Evp, Co Fo | 47,042 | 0 | 26 Feb, 2026 |
| Jeffrey M Leiden | Executive Chairman | 34,797 | 0 | 26 Feb, 2026 |
| Terrence C Kearney | - | 6,536 | 0 | 14 Aug, 2023 |
| Alan M Garber | - | 6,872 | 0 | 05 May, 2025 |
| Yuchun Lee | - | 1,875 | 0 | 31 Jan, 2023 |
| Amit Sachdev | Evp Chief Patient Ext Af Off | 55,570 | 0 | 26 Feb, 2026 |
| Michel Lagarde | - | 1,132 | 0 | 10 Oct, 2023 |
| Suketu Upadhyay | - | 2,354 | 0 | 05 May, 2025 |
| David Altshuler | Evp, Chief Scientific Officer | 34,477 | 0 | 26 Jan, 2026 |
| Stuart A Arbuckle | Evp, Coo | 63,368 | 0 | 02 Jul, 2025 |
| Sangeeta N. Bhatia | - | 4,299 | 0 | 18 Feb, 2026 |
| Reshma Kewalramani | Ceo President | 98,278 | 0 | 03 Mar, 2026 |
| Jonathan Biller | Evp And Chief Legal Officer | 13,659 | 0 | 26 Feb, 2026 |
| Diana Mckenzie | - | 2,231 | 0 | 05 May, 2025 |
| Jennifer Schneider | - | 1,718 | 0 | 05 May, 2025 |
| Ourania Tatsis | Evp, Chief Reg. Quality Off. | 46,763 | 0 | 26 Feb, 2026 |
| Carmen Bozic | Evp And Cmo | 33,076 | 0 | 31 Mar, 2026 |
| Nancy Thornberry | - | 2,035 | 0 | 05 May, 2025 |
| Bastiano Sanna | Evp, Cell Genetic Therapies | 32,038 | 0 | 09 May, 2023 |
| Joy Liu | Evp And Chief Legal Officer | 21,833 | 0 | 03 Apr, 2026 |
| Kristen Ambrose | Svp Chief Accounting Officer | 6,624 | 0 | 02 Mar, 2026 |
| Edward Morrow Iii Atkinson | Evp, Chief Technical Ops. Off. | 18,432 | 0 | 26 Feb, 2026 |
| Duncan Mckechnie | Evp, Chief Commercial Officer | 12,489 | 0 | 13 Mar, 2026 |
| Mark E. Bunnage | Evp, Chief Scientific Officer | 7,284 | 0 | 26 Feb, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 15 Apr, 2026 | Alan M Garber | Deferred Stock Units | A | 34 | $442.50 | 34 | D | A |
| 15 Apr, 2026 | Bruce I Sachs | Deferred Stock Units | A | 107 | $442.50 | 15,672 | D | A |
| 15 Apr, 2026 | Suketu Upadhyay | Deferred Stock Units | A | 81 | $442.50 | 2,799 | D | A |
| 01 Apr, 2026 | Joy Liu | Common Stock | D | 978 | $449.17 | 21,833 | D | S |
| 27 Mar, 2026 | Carmen Bozic | Common Stock | D | 2,329 | $450.95 | 33,076 | D | S |
| 13 Mar, 2026 | Carmen Bozic | Common Stock | D | 2,329 | $481.79 | 35,405 | D | S |
| 11 Mar, 2026 | Duncan Mckechnie | Common Stock | D | 2,633 | $498.42 | 12,489 | D | S |
| 04 Mar, 2026 | Duncan Mckechnie | Common Stock | D | 2,437 | $475.30 | 15,122 | D | S |
| 02 Mar, 2026 | Joy Liu | Common Stock | D | 892 | $495.96 | 22,811 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 400 | $479.75 | 137,878 | D | S |
| 27 Feb, 2026 | Carmen Bozic | Common Stock | D | 2,329 | $480.31 | 37,734 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 120 | $481.50 | 137,758 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 240 | $482.84 | 137,518 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 2,510 | $487.13 | 135,008 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 3,278 | $488.27 | 131,730 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 460 | $489.32 | 131,270 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 2,725 | $490.54 | 128,545 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 949 | $491.30 | 127,596 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 2,520 | $493.29 | 125,076 | D | S |
| 27 Feb, 2026 | Reshma Kewalramani | Common Stock | D | 3,498 | $494.33 | 121,578 | D | S |